This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Moleculin Biotech’s 8K filing here.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
See Also
- Five stocks we like better than Moleculin Biotech
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Palantir Cracks $50, Is There Still Time to Get on Board?
- The How And Why of Investing in Oil Stocks
- Insider Buying Signals Upside for These 3 Stocks
- Most active stocks: Dollar volume vs share volume
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
